



Mirtazapine in comorbid major depression and an alcohol use disorder: A double-blind placebo-controlled pilot trial



Jack R. Cornelius^{a,*}, Tammy Chung^a, Antoine B. Douaihy^a, Levent Kirisci^a, Jody Glance^a, Julie Kmiec^a, Douglas FitzGerald^a, Maribeth A. Wesesky^a, Ihsan Salloum^b

^a University of Pittsburgh, Western Psychiatric Institute and Clinic, 3811 O'Hara Street, Pittsburgh, PA 15213, USA

^b University of Miami, Department of Psychiatry, Miller School of Medicine, 1120 NW 14th Street, Miami, FL 33136, USA

ARTICLE INFO

Article history:

Received 11 February 2016

Received in revised form

7 June 2016

Accepted 9 June 2016

Available online 15 June 2016

Keywords:

Mirtazapine

Comorbid

Major depression

Alcohol use disorder

ABSTRACT

This was a first double-blind, placebo-controlled pilot study to evaluate the efficacy of the novel antidepressant mirtazapine for treating both the depressive symptoms and the level of alcohol consumption of subjects with comorbid major depressive disorder and an alcohol use disorder (MDD/AUD). The results of two previous studies of mirtazapine in MDD/AUD subjects had suggested efficacy for mirtazapine for decreasing their level of depressive symptoms, but level of alcohol consumption had not been assessed in those studies. All subjects in this 12-week pilot study were randomized to either mirtazapine or placebo, and also received motivational enhancement therapy. Between-group analyses involving the outcome measures of depressive symptoms, level of alcohol consumption, and level of alcohol craving indicated no significant differences between groups, possibly because of limited sample size. However, within-group *t* tests in the mirtazapine group showed a significant decrease in depressive symptoms by week 2, also noted at all subsequent assessments (weeks 3, 4, 6, 8, 10, and 12) during the 12-week study. In contrast, no significant decrease in depressive symptoms was noted in the placebo group until week 8. No evidence of efficacy was found for mirtazapine for decreasing level of alcohol consumption in MDD/AUD subjects.

© 2016 Elsevier Ireland Ltd. All rights reserved.

1. Introduction

Previous studies involving antidepressant medications among persons with co-occurring major depressive disorder and an alcohol use disorder (MDD/AUD) have focused on selective serotonin reuptake inhibitors (SSRIs) or tricyclic medications, and the results of those trials have been disappointing (Nunes and Levin, 2004; Cornelius et al., 2009). Similarly, a meta-analysis by Lovieno et al. (2011) concluded that the SSRIs have not shown efficacy in comorbid populations. Those same authors (Lovieno et al., 2011) also noted the complete lack of studies involving a number of newer antidepressants, such as mirtazapine, for treating comorbid populations. Importantly, mirtazapine was found to be superior to other antidepressant medications for treating depression in a large meta-analysis of 12 new-generation antidepressants (Cipriani et al., 2009). Mirtazapine is classified as a second generation antidepressant medication with a tetracyclic structure. It is unique in its pharmacological profile among the currently available antidepressants, unrelated to tricyclic antidepressants or SSRIs.

Our own research group recently conducted a first open label study evaluating the acute efficacy of mirtazapine for decreasing the depressive symptoms and the level of drinking of persons with comorbid MDD/AUD. The results of that study demonstrated robust within-group efficacy for mirtazapine for decreasing both the level of depressive symptoms and the level of alcohol consumption of that comorbid population (Cornelius et al., 2012). However, no placebo control group was utilized in that study, so the efficacy of mirtazapine versus placebo could not be assessed.

In the current report, we present findings from a first double-blind placebo-controlled pilot study to assess the efficacy of mirtazapine for decreasing both the depressive symptoms and the excessive alcohol consumption of persons with comorbid MDD/AUD. We hypothesized that mirtazapine would demonstrate evidence of within-group efficacy and between-group efficacy for decreasing depressive symptoms and alcohol use.

2. Methods

Prior to entry into this treatment protocol, written informed consent was obtained from all subjects after all procedures had been fully explained. The study was approved by the University of

* Corresponding author.

E-mail address: corneliusjr@upmc.edu (J.R. Cornelius).

Pittsburgh Institutional Review Board. Fourteen participants were recruited for this pilot study. Participants were required to be between 18 and 55 years of age at baseline, meet criteria for both current MDD and an AUD, and be eligible for outpatient treatment, to be included in the study. At the baseline assessment, participants were evaluated for the DSM-IV diagnoses of an AUD and MDD, using the MINI International Neuropsychiatric Interview (Sheehan et al., 1998). Inclusion criteria included the co-occurring presence of both current MDD and an AUD. Exclusion criteria included: (1) age less than 18 or over 55; (2) presence of psychotic symptoms or a diagnosis involving psychosis, (3) receiving psychotropic medication in the prior month; (4) current DSM diagnosis of dependence or abuse on substances other than alcohol, cannabis, nicotine, or caffeine; (5) current significant medical or neurological condition; (6) suicidal ideation in the last three months, or lifetime suicidal attempt; (7) positive pregnancy test or breastfeeding; (8) inability or unwillingness to use contraceptive methods; (9) inability to read or understand study forms; (10) pending incarceration; or (11) current participation in another research study.

Following completion of the baseline assessment, participants were treated using a double-blind, placebo-controlled study design. Participants were randomly assigned to receive mirtazapine or placebo administered in identical-looking opaque capsules. The study medication was taken once per day at bedtime. Subjects were given 15 mg of mirtazapine for the first two weeks of the trial and 30 mg for the remainder of the 12-week medication trial. Protocol assessments were conducted weekly in the first month and biweekly thereafter. Brief Motivational Enhancement Therapy (MET) was also provided at each assessment (Miller et al., 1992). MET has been shown to be an effective treatment of both the alcohol use and the depressive symptoms of persons with co-occurring MDD/AUD (Cornelius et al., 2009; Cornelius et al., 2010; Cornelius et al., 2011; Cornelius et al., 2012). Participant-rated depressive symptoms were assessed with the Beck Depression Inventory (BDI) (Beck et al., 1961). Drinking behavior was evaluated using the timeline follow-back method (TLFB) (Sobell, et al., 1988). Medication side effects were assessed using the Systematic Assessment for Treatment Emergent Events-Systematic Inquiry (SAFTEE/SI) (Levine et al., 1986). Recruitment for this pilot study was discontinued when time and money for the study were exhausted. The pilot study currently being reported was funded by a small grant (an R21 grant) rather than a larger R01 grant. Consequently, the length of the study (two years) was substantially shorter than the duration typically utilized in larger studies (five years), and the amount of money available per year was only a fraction of the money that would have been available in a study funded by a R01 mechanism.

2.1. Statistical analysis

Descriptive statistics were calculated for all variables. Continuous baseline measures were compared by paired *t* tests and by analysis of variance. Categorical baseline measures were compared by chi-square analysis, corrected for continuity. Outcome measures were compared by repeated measures ANOVA, using demographic characteristics as covariates, and by *t* tests. Statistical analyses were completed utilizing an intent-to-treat study design. All tests of significance were 2-tailed. An alpha level ≤ 0.05 was used to indicate statistical significance. All analyses were conducted using the Statistical Package for the Social Sciences, version 22.0 (IBM Corp., Released, 2013) and SAS 9.3 (SAS Institute, Inc, 2011).

3. Results

A total of 14 subjects participated in the study. Subjects included 10 (71%) males and 4 (29%) females. Half of the sample participants were Caucasian and half were African American. The mean age of study subjects was 41.3 years ($SD=8.8$). At baseline, the mirtazapine and placebo groups were not significantly different in distribution of any demographic variables or variables used as outcome measures. At baseline, subjects demonstrated moderately severe depressive symptoms, with a mean BDI of 26.9 ($SD=9.6$), which is typical of our outpatient MDD/AUD patients. At baseline, subjects demonstrated prominent alcohol consumption, with a mean of 6.6 drinks per drinking day ($SD=2.0$ drinks). Drinking occurred, on average, 72% of days ($SD=23\%$), and an average % heavy drinking days (five or more drinks per day) of 48%. An additional ten potential subjects signed informed consent for the study, but did not participate in the treatment study, because they were ruled out at baseline assessment. Reasons for exclusion from the study included the presence of psychotic symptoms ($n=4$), the absence of MDD at baseline ($n=2$), non-completion of the baseline assessment ($n=2$), the presence of cocaine abuse ($n=1$), and the discovery that the person was already participating in another research study ($n=1$) (Table 1).

Between-group analyses showed no significant differences in depressive symptoms or in level of alcohol consumption between the mirtazapine group and the placebo group at any time point. The repeated measures ANOVA group \times time interaction analyses (the primary outcome assessment analyses involving level of depressive symptoms) failed to show a significant difference between the two treatment groups in levels of BDI depressive symptoms ($F=0.71$, $p \geq 0.68$) (Table 2).

Within-group tests in the mirtazapine group showed a trend for a decrease in depressive symptoms ($p < 0.07$) as early as week 1, with a 32.1% decrease in BDI depressive symptoms noted by week 1 in the mirtazapine group. A statistically significant within-group decrease in depressive symptoms among the mirtazapine group was noted in week 2 of the study (47.2% decrease, $p=0.01$), and a statistically significant within-group decrease in level of depressive symptoms compared to baseline levels of depression was also noted at all subsequent assessments (weeks 3, 4, 6, 8, 10, and 12) during the 12-week study. At week 4, five of the seven mirtazapine group subjects had demonstrated $\geq 50\%$ decrease in BDI depressive symptoms, while only one person in the placebo group showed a 50% decrease in BDI depressive symptoms at that time, which was a trend towards a statistically significant between-group difference between the mirtazapine group and the placebo group (mean change=52.9% in the mirtazapine group versus a 23.1% change in the placebo group, $p=0.1$). In contrast, no significant within-group decrease in depressive symptoms was noted in the placebo group until week 8, with no within-group decreases in depressive symptoms being noted in the placebo group at weeks 2, 3, 4, or 6. Both treatment groups showed significant decreases in depressive symptoms by the end of the clinical trial (week 12), but no between-group differences in depressive symptoms were noted at any time point.

During the 12-week course of the study, no significant between-group differences were noted on any measure of drinking (Table 4). Indeed, the level of drinking in the mirtazapine group was slightly higher than in the placebo group, though the difference between groups was not statistically significant. Also, craving for alcohol, as measured on the Obsessive Compulsive Drinking Scale (Anton, 2000), showed a significant decrease in each of the treatment groups during the course of the study, but no significant between group difference was noted at any time point (Table 3).

Mirtazapine was well tolerated in the study. There were no serious adverse events during the study. Only one potential

Table 1
Demographic and Clinical Characteristics of Randomized Subjects.

	Total (n=14)		Placebo (n=7)		Mirtazapine (n=7)		χ^2	sig
Sex (% female)	28.6%		14.3%		42.9%		1.40	0.6
Ethnic (% white)	50.0%		71.4%		28.6%		2.57	0.3
Baseline	Mean	S.D.	Mean	S.D.	Mean	S.D.	t	sig
BDI Total	26.9	9.6	26.1	11.7	27.6	7.7	–0.27	0.8
OCDS Total	24.2	7.4	24.3	7.8	24.1	7.7	0.04	1.0
Drinks per Week	33.6	13.6	37.1	14.5	30.0	12.6	0.98	0.3
Drinks per drinking day	6.6	2.0	6.9	1.7	6.4	2.4	0.47	0.4
Days of Alcohol Use per Week	5.2	1.9	5.4	2.0	5.0	2.0	0.40	0.7
Heavy Drinking Days / Week	3.5	1.6	3.9	1.2	3.1	1.9	0.85	0.4
Week 12								
BDI Total	9.5	6.6	10.1	8.7	8.9	4.4	0.35	0.7
OCDS Total	12.9	5.6	11.6	6.7	14.1	4.4	–0.85	0.4
Drinks per Week	24.9	16.8	24.0	16.3	25.7	18.7	–0.18	0.9
Drinks per drinking day	3.9	1.5	4.4	1.5	3.5	1.6	1.06	0.3
Days of Alcohol Use per Week	6.4	5.4	6.4	6.0	6.4	5.1	0.00	1.0
Heavy Drinking Days / Week	1.6	1.2	1.4	1.3	1.9	1.1	–0.68	0.5
Change from Baseline to Week 12								
Δ BDI Total	–17.4	8.5	–16.0	11.0	–18.7	5.7	0.58	0.6
Δ OCDS Total	–11.4	7.0	–12.7	7.4	–10.0	6.9	–0.71	0.5
Δ Drinks per Week	–8.7	20.4	–13.1	19.6	–4.3	21.8	–0.80	0.4
Δ Drinks per drinking day	–2.7	2.8	–2.5	2.0	–2.9	3.7	0.20	0.8
Δ Days of Alcohol Use / Week	+1.2	4.5	+1.0	5.1	+1.4	4.2	–0.17	0.9
Δ Heavy Drinking Days / Week	–1.9	1.7	–2.4	1.3	–1.3	2.0	–1.29	0.2

Note: BDI=Beck Depression Inventory, OCDS=Obsessive Compulsive Drinking Scale, S.D.=Standard Deviation, sig=statistical significance.

Table 2
Beck Depression Inventory total.

The GLM procedure					
Repeated measures analysis of variance					
Tests of hypotheses for between subjects effects					
Source	DF	Type III SS	Mean Square	F Value	Pr > F
TxArm	1	10.151604	10.151604	0.02	0.8908
Gender	1	16.719417	16.719417	0.03	0.8602
Race	1	893.929381	893.929381	1.75	0.2158
Error	10	5119.654393	511.965439		

The GLM procedure							
Repeated measures analysis of variance							
Univariate tests of hypotheses for within subject effects							
Source	DF	Type III SS	Mean Square	F Value	Pr > F	Adj Pr > F	
						G - G	H-F-L
Time	8	2572.412937	321.551617	10.58	< 0.0001	< 0.0001	< 0.0001
Time*TxArm	8	173.608732	21.701092	0.71	0.6784	0.5863	0.6584
Time*gender	8	486.755999	60.844500	2.00	0.0566	0.1134	0.0680
Time*race	8	109.386510	13.673314	0.45	0.8872	0.7704	0.8649
Error(time)	80	2431.363049	30.392038				

Greenhouse-Geisser (G-G) Epsilon						0.4961
Huynh-Feldt-Lecoutre (H-F-L) Epsilon						0.8632

Notes: GLM=Generalized Linear Model; DF=degrees of freedom, SS=sums of squares, TxArm=treatment arm, Pr=probability, Adj Pr=Adjusted probability.

medication side effect, weight gain, occurred significantly more commonly in the treatment group than placebo group during the course of the study. The mirtazapine group gained an average of 2.36 kg (SD=1.69 kg; range=0 to 4.08) compared to the placebo group's average of 0.57 kg (SD=1.24 kg; range=–1.36 [weight loss] to 1.79) (independent *t* test=0.04). In contrast, there were no significant differences between the mirtazapine and placebo groups in reports of sedation at any week across the entire study (Fig. 1).

4. Discussion

This report provides data from what we believe is the first double-blind, placebo-controlled study evaluating the safety and efficacy of the second generation antidepressant medication mirtazapine for the treatment of both the depressive symptoms and the level of alcohol use of persons with comorbid MDD/AUD. Mirtazapine was well tolerated in our study. The current study was largely negative for both depressive symptoms and alcohol

Table 3
Craving-Obsessive Compulsive Drinking Scale.

The GLM procedure					
Repeated measures analysis of variance					
Tests of hypotheses for between subjects effects					
Source	DF	Type III SS	Mean Square	F Value	Pr > F
TxArm	1	217.349740	217.349740	0.81	0.3892
Gender	1	175.269140	175.269140	0.65	0.4377
Race	1	259.226283	259.226283	0.97	0.3488
Error	10	2682.670543	268.267054		

The GLM procedure							
Repeated measures analysis of variance							
Univariate tests of hypotheses for within subject effects							
Source	DF	Type III SS	Mean Square	F Value	Pr > F	Adj Pr > F	
						G - G	H-F-L
Time	8	1290.282821	161.285353	7.57	< 0.0001	0.0001	< 0.0001
Time*TxArm	8	81.768939	10.221117	0.48	0.8671	0.7451	0.8380
Time*gender	8	171.293983	21.411748	1.01	0.4388	0.4150	0.4337
Time*race	8	62.241602	7.780200	0.37	0.9358	0.8266	0.9127
Error(time)	80	1703.980620	21.299758				

Notes: GLM= Generalized Linear Model; DF= degrees of freedom, SS= sums of squares, TxArm=treatment arm, Pr=probability, Adj Pr=Adjusted probability, G-G= Greenhouse-Geisser, H-F-L= Huynh-Feldt-Lecoutre.

Table 4
Drinks per drinking day.

The GLM procedure						
Repeated measures analysis of variance						
Tests of hypotheses for between subjects effects						
Source	DF	Type III SS	Mean Square	F Value	Pr > F	
TxArm	1	15.9580321	15.9580321	0.87	0.3717	
Gender	1	14.7950900	14.7950900	0.81	0.3890	
Race	1	20.0786948	20.0786948	1.10	0.3189	
Error	10	182.4545451	18.2454545			
The GLM procedure						
Repeated measures analysis of variance						
Univariate tests of hypotheses for within subject effects						
Source	DF	Type III SS	Mean Square	F Value	Pr > F	Adj Pr > F
						G - G
						H-F-L
Time	8	100.4376594	12.5547074	4.07	0.0004	0.0074
Time*TxArm	8	6.5170015	0.8146252	0.26	0.9756	0.8988
Time*gender	8	29.3626256	3.6703282	1.19	0.3158	0.3302
Time*race	8	32.8582675	4.1072834	1.33	0.2403	0.2752
Error(time)	80	246.8338022	3.0854225			0.2491
Greenhouse-Geisser (G-G) Epsilon						0.4983
Huynh-Feldt-Lecoutre (H-F-L) Epsilon						0.8699

Notes: GLM=Generalized Linear Model; DF=degrees of freedom, SS= sums of squares, TxArm= treatment arm, Pr=probability, Adj Pr=Adjusted probability.

consumption in the absence of a significant time x group interaction in the repeated measures ANOVA. Nonetheless, a within-group improvement in depressive symptoms was noted earlier in the mirtazapine group than in the placebo group, being noted as a trend at week 1 and as a statistically significant difference at week 2 and at all subsequent assessments (weeks 2, 3, 4, 6, 8, 10, and 12), while in the placebo group a significant within-group decrease in depressive symptoms was not noted until week 8. Thus, our current preliminary findings demonstrate early and sustained within-group efficacy for mirtazapine for decreasing the level of

depressive symptoms in MDD/AUD. This difference in the timing of the response of depressive symptoms to mirtazapine versus to placebo could be clinically significant for some patients, because some patients may not be willing to wait two months or longer for a therapeutic response to their treatment, whereas a response to mirtazapine might be seen in as little as two weeks. Therefore, despite the negative between-group findings of the current study, the significant within-group findings concerning depressive symptoms suggest some level of promise for mirtazapine for decreasing the level of depressive symptoms of MDD/AUD patients.




Fig. 1. Depressive Symptoms as 21-item Beck Depression Inventory Means for Placebo and Mirtazapine Groups.

Our current findings concerning the rapid onset of action of mirtazapine for decreasing depressive symptoms is consistent with the results of a review by [Watanabe et al., \(2008\)](#), which found that a rapid onset of effect for treating depressive symptoms is typical of treatment with mirtazapine.

The significant within-group decrease in depressive symptoms noted during the course of the current treatment trial is consistent with the within-group finding of an open label study by [Yoon et al. \(2006\)](#) conducted in South Korea and the between-group findings of a double-blind study by [Altintoprak et al. \(2008\)](#) conducted in Turkey. Both of those studies reported significant decreases in depressive symptoms in their studies of comorbid subjects involving mirtazapine. However, those two previous studies did not evaluate the level of alcohol use during the course of their studies, so we cannot compare the results of the current study to the results from those two previous studies on the important outcome variable of level of alcohol use. Our current findings also extend those previously reported findings by demonstrating no evidence of efficacy for mirtazapine for decreasing the level of alcohol consumption of that comorbid MDD/AUD population.

The results of this study should be interpreted in light of some limitations. The biggest limitation of this pilot study was its limited sample size. Large differences would have been required to demonstrate significant differences between groups with the current sample size. Also, since all of the subjects in this study were recruited as outpatients, it is unclear to what extent the results of this study apply to inpatients or to patients with additional co-occurring substance use disorders. In addition, we cannot rule out the possibility that some of the therapeutic effect that was noted in this clinical trial may have resulted from the brief motivation enhancement therapy used in study. Large double-blind placebo-controlled trials of mirtazapine appear to be warranted in persons with comorbid disorders.

Acknowledgements

This research was supported in part by Grants from the

National Institute on Alcohol Abuse and Alcoholism (R21 AA022123, R21 AA022863, R01 AA013370, R01 AA015173, K24 AA15320); and from the National Institute on Drug Abuse (R01 DA019142, P50 DA05605, K02 DA017822).

Presented in part at the 25th Annual Meeting of the American Academy of Addiction Psychiatry (AAAP), Huntington Beach, California, December 3–6, 2015.

References

- Altintoprak, A.E., Zorlu, N., Coskunol, H., Akdeniz, F., Kitapcioglu, G., 2008. Effectiveness and tolerability of mirtazapine and amitriptyline in alcoholic patients with co-morbid depressive disorder: A randomized, double-blind study. *Hum. Psychopharmacol.* 23, 313–319.
- Anton, R.F., 2000. Obsessive-compulsive aspects of craving: Development of the Obsessive Compulsive Drinking Scale. *Addiction* 95 (Suppl. 2), S211–S217.
- Beck, A.T., Ward, C.H., Mendelson, M., Mock, J., Erbaugh, J., 1961. An inventory for measuring depression. *Arch. Gen. Psychiatry* 4, 561–571.
- Cipriani, A., Furukawa, T.A., Salanti, G., Geddes, J.R., Higgins, J.P., Churchill, R., Barbui, C., 2009. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. *Lancet* 373, 746–758.
- Cornelius, J.R., Bukstein, O.G., Douaihy, A.B., Clark, D.B., Chung, T.A., Daley, D.C., Wood, D.S., Brown, S.J., 2010. Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults. *Drug Alcohol Depend.* 112, 39–45.
- Cornelius, J.R., Bukstein, O.G., Wood, D.S., Kirisci, L., Douaihy, A.B., Clark, D.B., 2009. Double-blind placebo-controlled trial of fluoxetine in adolescents with comorbid major depression and an alcohol use disorder. *Addict. Behav.* 34, 905–909.
- Cornelius, J.R., Douaihy, A.B., Bukstein, O.D., Daley, D.C., Wood, D.S., Kelly, T.M., Salloum, I.M., 2011. Evaluation of cognitive behavioral therapy/motivation enhancement therapy (CBT/MET) in a treatment trial of comorbid alcohol use disorder/ major depressive disorder adolescents. *Addict. Behav.* 36, 843–848.
- Cornelius, J.R., Douaihy, A.B., Clark, D.B., Chung, T., Wood, D.S., Daley, D., 2012. Mirtazapine in comorbid major depression and alcohol dependence: an open-label trial. *J. Dual Diagn.* 8, 2000–2004.
- IBM Corp., Released, 2013. IBM SPSS Statistics for Windows, Version 22.0. IBM Corp., Armonk, NY.
- Levine, J., Schooler, R.N., 1986. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. *Psychopharmacol. Bull.* 22, 343–381.
- Lovieno, N., Tedeschi, E., Bentley, K.H., Evins, A.E., Papakostas, G.I., 2011. Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials. *J. Clin. Psychiatry* 72, 1144–1151.
- Miller, W.R., Zweben, A., DiClemente, C.C., Rychtarik, R.G., 1992. Motivational Enhancement Therapy Manual. Project MATCH Monograph Series, Volume 2. National Institute on Alcohol Abuse and Alcoholism, Washington, DC.
- Nunes, E.V., Levin, F.B., 2004. Treatment of depression in patients with alcohol or other drug dependence. A meta-analysis. *JAMA* 291, 1887–1896.
- SAS Institute, Inc., 2011. Base SAS 9.3 Procedures Guide. SAS Institute, Inc., Cary, N.C.
- Sheehan, D.V., Lecrubier, Y., Sheehan, H., Amorim, P., Janars, J., Weiller, E., Dunbar, G.C., 1998. The Mini-International Neuropsychiatric Interview (Mini): The Development and Validation of a Structured Diagnostic Psychiatric Interview for DSM-IV and ICD-10. *J. Clin. Psychiatry* 59 (Suppl. 20), 22–33.
- Sobell, L.D., Sobell, M.B., Leo, G.I., Cancilla, A., 1988. Reliability of a timeline method: Assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations. *Br. J. Addict.* 83, 393–402.
- Watanabe, N., Omori, I.M., Nakagawa, A., Cipriani, A., Barbui, C., Furukawa, T.A., 2008. Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: Systematic review and meta-analysis. *J. Clin. Psychiatry* 69, 1404–1415.
- Yoon, S.J., Pae, C.U., Kim, D.J., Namkoong, K., Lee, E., Oh, D.Y., Lee, C.T., 2006. Mirtazapine for patients with alcohol dependence and comorbid depressive disorders: a multicentre, open label study. *Prog. Neuro-Psychopharmacol. Biol. Psychiatry* 30, 1196–1201.